Aberrant Expression of Osteopontin and E-Cadherin Indicates Radiation Resistance and Poor Prognosis for Patients with Cervical Carcinoma

Journal of Histochemistry and Cytochemistry

Volumn 63, Issue 2, 2015, Pages 88-98

  Huang, Xinqiong ^a   Qian, Yujie ^a   Wu, Hainan ^b   Xie, Xiaoxue ^c   Zhou, Qin ^a   Wang, Ying ^a   Kuang, Weilu ^a   Shen, Lin ^a,d   Li, Kai ^a   Su, Juan ^a   Shen, Liangfang ^a,d   Chen, Xiang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Department of Clinical Medicine the NCO School of the Border Control Force   (China)

^c HUNAN CANCER HOSPITAL   (China)

^d CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

E cadherin; epithelial mesenchymal transition; immunohistochemistry; locally advanced cervical squamous cell carcinoma; osteopontin; radiation resistance

Indexed keywords

ANTINEOPLASTIC AGENT; OSTEOPONTIN; TUMOR MARKER; UVOMORULIN; CADHERIN;

ADULT; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FIGO STAGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; RETROSPECTIVE STUDY; UTERINE CERVIX CARCINOMA; AGED; CARCINOMA, SQUAMOUS CELL; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PATHOLOGY; RADIATION RESPONSE; RADIATION TOLERANCE; UTERINE CERVICAL NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CADHERINS; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; OSTEOPONTIN; RADIATION TOLERANCE; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS;

EID: 84921486734     PISSN: 00221554     EISSN: 15515044     Source Type: Journal    
DOI: 10.1369/0022155414561329     Document Type: Article

References (58)

1. Anborgh PH,Mutrie JC,Tuck AB,Chambers AF.Role of the metastasis-promoting protein osteopontin in the tumour microenvironment.J Cell Mol Med. 2010;14:2037-2044
2. Armstrong AJ,Marengo MS,Oltean S,Kemeny G,Bitting RL,Turnbull JD,Herold CI,Marcom PK,George DJ,Garcia-Blanco MA.Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.Mol Cancer Res. 2011;9:997-1007
3. Ashkar S,Weber GF,Panoutsakopoulou V,Sanchirico ME,Jansson M,Zawaideh S,Rittling SR,Denhardt DT,Glimcher MJ,Cantor H.Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity.Science. 2000;287:860-864
4. Avanzo M,Stancanello J,Franchin G,Sartor G,Jena R,Drigo A,Dassie A,Gigante M,Capra E.Correlation of a hypoxia based tumor control model with observed local control rates in nasopharyngeal carcinoma treated with chemoradiotherapy.Med Phys. 2010;37:1533-1544
5. Bache M,Reddemann R,Said HM,Holzhausen HJ,Taubert H,Becker A,Kuhnt T,Hänsgen G,Dunst J,Vordermark D.Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels.Int J Radiat Oncol Biol Phys. 2006;66:1481-1487
6. Bae GY,Choi SJ,Lee JS,Jo J,Lee J,Kim J,Cha HJ.Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer.Oncotarget. 2013;4:2512-2522
7. Bouchat V,Nuttens VE,Michiels C,Masereel B,Feron O,Gallez B,Vander Borght T,Lucas S.Radioimmunotherapy with radioactive nanoparticles: biological doses and treatment efficiency for vascularized tumors with or without a central hypoxic area.Med Phys. 2010;37:1826-1839
8. Chang SH,Minai-Tehrani A,Shin JY,Park S,Kim JE,Yu KN,Hong SH,Hong CM,Lee KH,Beck GR,Cho MH.Beclin1-induced autophagy abrogates radioresistance of lung cancer cells by suppressing osteopontin.J Radiat Res. 2012;53:422-432
9. Cheng Y,Zhou Y,Jiang W,Yang X,Zhu J,Feng D,Wei Y,Li M,Yao F,Hu W,Xiao W,Ling B.Significance of E-cadherin, beta-catenin, and vimentin expression as postoperative prognosis indicators in cervical squamous cell carcinoma.Hum Pathol. 2012;43:1213-1220
10. Cho H,Hong SW,Oh YJ,Kim MA,Kang ES,Lee JM,Kim SW,Kim SH,Kim JH,Kim YT,Lee K.Clinical significance of osteopontin expression in cervical cancer.J Cancer Res Clin Oncol. 2008;134:909-917
11. De Craene B,Berx G.Regulatory networks defining EMT during cancer initiation and progression.Nature Rev Cancer. 2013;13:97-110
12. Escriva M,Peiro S,Herranz N,Villagrasa P,Dave N,Montserrat-Sentís B,Murray SA,Francí C,Gridley T,Virtanen I,García de Herreros A.Repression of PTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced apoptosis.Mol Cell Biol. 2008;28:1528-1540
13. Eyler CE,Rich JN.Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis.J Clin Oncol. 2008;26:2839-2845
14. Ferlay J,Shin HR,Bray F,Forman D,Mathers C,Parkin DM.Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.Int J Cancer. 2010;127:2893-2917
15. Forootan SS,Foster CS,Aachi VR,Adamson J,Smith PH,Lin K,Ke Y.Prognostic significance of osteopontin expression in human prostate cancer.Int J Cancer. 2006;118:2255-2261
16. Forouzanfar MH,Foreman KJ,Delossantos AM,Lozano R,Lopez AD,Murray CJ,Naghavi M.Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis.Lancet. 2011;378:1461-1484
17. Furuyama H,Arii S,Mori A,Imamura M.Role of E-cadherin in peritoneal dissemination of the pancreatic cancer cell line, panc-1, through regulation of cell to cell contact.Cancer Lett. 2000;157:201-209
18. Gomez-Casal R,Bhattacharya C,Ganesh N,Bailey L,Basse P,Gibson M,Epperly M,Levina V.Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes.Mol Cancer. 2013;12:94
19. Hahne JC,Meyer SR,Kranke P,Dietl J,Guckenberger M,Polat B,Hönig A.Studies on the role of osteopontin-1 in endometrial cancer cell lines.Strahlentherapie Und Onkologie. 2013;189:1040-1048
20. Hahnel A,Wichmann H,Kappler M,Kotzsch M,Vordermark D,Taubert H,Bache M.Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells.Radiat Oncol. 2010;5:82
21. Hittelman WN,Liao Y,Wang L,Milas L.Are cancer stem cells radioresistant?.Future Oncol. 2010;6:1563-1576
22. Inoue A,Seidel MG,Wu W,Kamizono S,Ferrando AA,Bronson RT,Iwasaki H,Akashi K,Morimoto A,Hitzler JK,Pestina TI,Jackson CW,Tanaka R,Chong MJ,McKinnon PJ,Inukai T,Grosveld GC,Look AT.Slug, a highly conserved zinc finger transcriptional repressor, protects hematopoietic progenitor cells from radiation-induced apoptosis in vivo.Cancer Cell. 2002;2:279-288
23. Kim DH,Lee JH,Ki YK,Nam JH,Kim WT,Jeon HS,Park D,Kim DW.Short-course palliative radiotherapy for uterine cervical cancer.Radiat Oncol J. 2013;31:216-221
24. Kim TJ,Lee JW,Song SY,Choi JJ,Choi CH,Kim BG,Lee JH,Bae DS.Increased expression of pAKT is associated with radiation resistance in cervical cancer.Br J Cancer. 2006;94:1678-1682
25. Le QT,Sutphin PD,Raychaudhuri S,Yu SC,Terris DJ,Lin HS,Lum B,Pinto HA,Koong AC,Giaccia AJ.Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas.Clin Cancer Res. 2003;9:59-67
26. Li NY,Weber CE,Mi Z,Wai PY,Cuevas BD,Kuo PC.Osteopontin up-regulates critical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype.J Am Coll Surg. 2013;217:17-26
27. Liu J,Zhang J,Wang X,Li Y,Chen Y,Li K,Zhang J,Yao L,Guo G.HIF-1 and NDRG2 contribute to hypoxia-induced radioresistance of cervical cancer Hela cells.Exp Cell Res. 2010;316:1985-1993
28. Mani SA,Guo W,Liao MJ,Eaton EN,Ayyanan A,Zhou AY,Brooks M,Reinhard F,Zhang CC,Shipitsin M,Campbell LL,Polyak K,Brisken C,Yang J,Weinberg RA.The epithelial-mesenchymal transition generates cells with properties of stem cells.Cell. 2008;133:704-715
29. Mareel M,Oliveira MJ,Madani I.Cancer invasion and metastasis: interacting ecosystems.Virchows Archiv. 2009;454:599-622
30. Mi Z,Bhattacharya SD,Kim VM,Guo H,Talbot LJ,Kuo PC.Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis.Carcinogenesis. 2011;32:477-487
31. Mi Z,Guo H,Russell MB,Liu Y,Sullenger BA,Kuo PC.RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells.Mol Ther. 2009;17:153-161
32. Moeller BJ,Richardson RA,Dewhirst MW.Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment.Cancer Metastasis Rev. 2007;26:241-248
33. Nakano T,Ohno T,Ishikawa H,Suzuki Y,Takahashi T.Current advancement in radiation therapy for uterine cervical cancer.J Radiat Res. 2010;51:1-8
34. Onder TT,Gupta PB,Mani SA,Yang J,Lander ES,Weinberg RA.Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways.Cancer Res. 2008;68:3645-3654
35. Perez-Caro M,Bermejo-Rodriguez C,Gonzalez-Herrero I,Sánchez-Beato M,Piris MA,Sánchez-García I.Transcriptomal profiling of the cellular response to DNA damage mediated by Slug (Snai2).Br J Cancer. 2008;98:480-488
36. Perez-Losada J,Sanchez-Martin M,Perez-Caro M,Pérez-Mancera PA,Sánchez-García I.The radioresistance biological function of the SCF/kit signaling pathway is mediated by the zinc-finger transcription factor Slug.Oncogene. 2003;22:4205-4211
37. Raimondi C,Gianni W,Cortesi E,Gazzaniga P.Cancer stem cells and epithelial-mesenchymal transition: revisiting minimal residual disease.Curr Cancer Drug Targets. 2010;10:496-508
38. Randall LM,Monk BJ,Moon J,Parker R,Al-Ghazi M,Wilczynski S,Fruehauf JP,Markman M,Burger RA.Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group Study.Gynecologic Oncology. 2010;119:417-421
39. Reya T,Morrison SJ,Clarke MF,Weissman IL.Stem cells, cancer, and cancer stem cells.Nature. 2001;414:105-111
40. Rittling SR,Chambers AF.Role of osteopontin in tumour progression.Br J Cancer. 2004;90:1877-1881
41. Rose PG.Chemoradiotherapy: the new standard care for invasive cervical cancer.Drugs. 2000;60:1239-1244
42. Rud AK,Boye K,Oijordsbakken M,Lund-Iversen M,Halvorsen AR,Solberg SK,Berge G,Helland A,Brustugun OT,Mælandsmo GM.Osteopontin is a prognostic biomarker in non-small cell lung cancer.BMC Cancer. 2013;13:540
43. Said HM,Hagemann C,Staab A,Stojic J,Kühnel S,Vince GH,Flentje M,Roosen K,Vordermark D.Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo.Radiother Oncol. 2007;83:398-405
44. Scanlon CS,Van Tubergen EA,Inglehart RC,D’Silva RJ.Biomarkers of epithelial-mesenchymal transition in squamous cell carcinoma.J Dent Res. 2013;92:114-121
45. Scheel C,Weinberg RA.Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links.Semin Cancer Biol. 2012;22:396-403
46. Solberg TD,Nearman J,Mullins J,Li S,Baranowska-Kortylewicz J.Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy.Int J Radiat Oncol Biol Phys. 2008;72:918-926
47. Song JY,Lee JK,Lee NW,Yeom BW,Kim SH,Lee KW.Osteopontin expression correlates with invasiveness in cervical cancer.Aust N Z J Obstet Gynaecol. 2009;49:434-438
48. Tang H,Wang J,Bai F,Zhai H,Gao J,Hong L,Xie H,Zhang F,Lan M,Yao W,Liu J,Wu K,Fan D.Positive correlation of osteopontin, cyclooxygenase-2 and vascular endothelial growth factor in gastric cancer.Cancer Invest. 2008;26:60-67
49. Theys J,Jutten B,Habets R,Paesmans K,Groot AJ,Lambin P,Wouters BG,Lammering G,Vooijs M.E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells.Radiother Oncol. 2011;99:392-397
50. Thiery JP.Epithelial-mesenchymal transitions in tumour progression.Nature Rev Cancer. 2002;2:442-454
51. Thiery JP,Acloque H,Huang RY,Nieto MA.Epithelial-mesenchymal transitions in development and disease.Cell. 2009;139:871-890
52. Vega S,Morales AV,Ocaña OH,Valdés F,Fabregat I,Nieto MA.Snail blocks the cell cycle and confers resistance to cell death.Genes Dev. 2004;18:1131-1143
53. Wang D,Su L,Huang D,Zhang H,Shin DM,Chen ZG.Downregulation of E-Cadherin enhances proliferation of head and neck cancer through transcriptional regulation of EGFR.Mol Cancer. 2011;10:116
54. Xu L,Jiang Y,Zheng J,Xie G,Li J,Shi L,Fan S.Aberrant expression of beta-catenin and E-cadherin is correlated with poor prognosis of nasopharyngeal cancer.Human Pathol. 2013;44:1357-1364
55. Yang J,Weinberg RA.Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis.Dev Cell. 2008;14:818-829
56. Yang L,Zhao W,Zuo WS,Wei L,Song XR,Wang XW,Zheng G,Zheng MZ.Silencing of osteopontin promotes the radiosensitivity of breast cancer cells by reducing the expression of hypoxia inducible factor 1 and vascular endothelial growth factor.Chin Med J (Engl). 2012;125:293-299
57. Zeisberg M,Neilson EG.Biomarkers for epithelial-mesenchymal transitions.J Clin Inv. 2009;119:1429-1437
58. Zhang CH,Xu GL,Jia WD,Ge YS,Li JS,Ma JL,Ren WH.Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis.Int J Cancer. 2012;130:2685-2692